-
1Academic Journal
Authors: Zh. V. Bryantseva, S. N. Novikov, D. G. Ulrikh, P. V. Krivorotko, I. A. Akulova, T. S. Yaganova, T. T. Tabagua, K. Yu. Zernov, A. M. Belyaev, Ж. В. Брянцева, С. Н. Новиков, Д. Г. Ульрих, П. В. Криворотько, И. А. Акулова, Т. С. Яганова, Т. Т. Табагуа, К. Ю. Зернов, А. М. Беляев
Source: Siberian journal of oncology; Том 23, № 6 (2024); 22-31 ; Сибирский онкологический журнал; Том 23, № 6 (2024); 22-31 ; 2312-3168 ; 1814-4861
Subject Terms: реконструктивная неудача, radiotherapy, hypofractionation, reconstruction, capsular contracture, reconstructive failure, лучевая терапия, гипофракционирование, реконструкция молочной железы, капсулярная контрактура
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/3350/1295; Gutowski K.S., Chwa E.S., Weissman J.P., Garg S.P., Simmons C.J., Brandt K.E., Gosain A.K. Practice Profile of Practicing Plastic Surgeons: A 20-year Review of Plastic Surgery Statistics. Plast Reconstr Surg Glob Open. 2023; 11(12). doi:10.1097/GOX.0000000000005486.; EBCTCG (Early Breast Cancer Trialists’ Collaborative Group); McGale P., Taylor C., Correa C., Cutter D., Duane F., Ewertz M., Gray R., Mannu G., Peto R., Whelan T., Wang Y., Wang Z., Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935): 2127–35. doi:10.1016/S0140-6736(14)60488-8. Erratum in: Lancet. 2014; 384(9957): 1848.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023; 402(10416): 1991–2003. doi:10.1016/S0140-6736(23)01082-6.; Брянцева Ж.В., Новиков С.Н., Ульрих Д.Г., Криворотько П.В., Акулова И.А., Яганова Т.С., Табагуа Т.Т., Зернов К.Ю. Влияние адъювантной лучевой терапии на косметические результаты после одномоментной реконструкции молочной железы с использованием тканевого экспандера и постоянного импланта. Опухоли женской репродуктивной системы. 2024; 20(2): 24–31. doi:10.17650/1994-4098-2024-16-2-24-31.; Zugasti A., Hontanilla B. The Impact of Adjuvant Radiotherapy on Immediate Implant-based Breast Reconstruction Surgical and Satisfaction Outcomes: A Systematic Review and Meta-analysis. Plast Reconstr Surg Glob Open. 2021; 9(11). doi:10.1097/GOX.0000000000003910.; Du F., Liu R., Zhang H., Xiao Y., Long X. Post-mastectomy adjuvant radiotherapy for direct-to-implant and two-stage implant-based breast reconstruction: A meta-analysis. J Plast Reconstr Aesthet Surg. 2022; 75(9): 3030–40. doi:10.1016/j.bjps.2022.06.063.; Kaidar-Person O., Vrou Offersen B., Hol S., Arenas M., Aristei C., Bourgier C., Cardoso M.J., Chua B., Coles C.E., Engberg Damsgaard T., Gabrys D., Jagsi R., Jimenez R., Kirby A.M., Kirkove C., Kirova Y., Kouloulias V., Marinko T., Meattini I., Mjaaland I., Nader Marta G., Witt Nystrom P., Senkus E., Skyttä T., Tvedskov T.F., Verhoeven K., Poortmans P. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother Oncol. 2019; 137: 159–66. doi:10.1016/j.radonc.2019.04.010.; Meattini I., Becherini C., Boersma L., Kaidar-Person O., Marta G.N., Montero A., Offersen B.V., Aznar M.C., Belka C., Brunt A.M., Dicuonzo S., Franco P., Krause M., MacKenzie M., Marinko T., Marrazzo L., Ratosa I., Scholten A., Senkus E., Stobart H., Poortmans P., Coles C.E. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022; 23(1): 21–31. doi:10.1016/S1470-2045-(21)00539-8.; Tramm T., Kaidar-Person O. Optimising post-operative radiation therapy after oncoplastic and reconstructive procedures. Breast. 2023; 69: 366–74. doi:10.1016/j.breast.2023.03.013.; Brunt A.M., Haviland J.S., Wheatley D.A., Sydenham M.A., Bloomfield D.J., Chan C., Cleator S., Coles C.E., Donovan E., Fleming H., Glynn D., Goodman A., Griffin S., Hopwood P., Kirby A.M., Kirwan C.C., Nabi Z., Patel J., Sawyer E., Somaiah N., Syndikus I., Venables K., Yarnold J.R., Bliss J.M.; FAST-Forward Trial Management Group. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. Health Technol Assess. 2023; 27(25): 1–176. doi:10.3310/WWBF1044.; Chung S.Y., Chang J.S., Shin K.H., Kim J.H., Park W., Kim H., Kim K., Lee I.J., Yoon W.S., Cha J., Lee K.C., Kim J.H., Choi J.H., Ahn S.J., Ha B., Lee S.Y., Lee D.S., Lee J., Shin S.O., Lee S.W., Choi J., Kim M.Y., Kim Y.J., Im J.H., Suh C.O., Kim Y.B. Impact of radiation dose on complications among women with breast cancer who underwent breast reconstruction and post-mastectomy radiotherapy: A multi-institutional validation study. Breast. 2021; 56: 7–13. doi:10.1016/j.breast.2021.01.003.; Тимошкина Е.В., Ткачев С.И., Глебовская В.В., Трофимова О.П., Черных М.В., Иванов С.М. Влияние гипофракционного режима адъювантной лучевой терапии на частоту осложнений у больных раком молочной железы с одномоментной реконструкцией синтетическими материалами. Медицинский алфавит. 2023; (10): 18–24. doi:10.33667/2078-5631-2023-10-18-24.; Kim D.Y., Park E., Heo C.Y., Jin U.S., Kim E.K., Han W., Shin K.H., Kim I.A. Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis. Breast. 2021; 55: 37–44. doi:10.1016/j.breast.2020.11.020.; Vinsensia M., Schaub R., Meixner E., Hoegen P., Arians N., Forster T., Hoeltgen L., Köhler C., Uzun-Lang K., Batista V., König L., Zivanovic O., Hennigs A., Golatta M., Heil J., Debus J., Hörner-Rieber J. Incidence and Risk Assessment of Capsular Contracture in Breast Cancer Patients following Post-Mastectomy Radiotherapy and Implant-Based Reconstruction. Cancers (Basel). 2024; 16(2): 265. doi:10.3390/cancers16020265.; Wang S.L., Fang H., Song Y.W., Wang W.H., Hu C., Liu Y.P., Jin J., Liu X.F., Yu Z.H., Ren H., Li N., Lu N.N., Tang Y., Tang Y., Qi S.N., Sun G.Y., Peng R., Li S., Chen B., Yang Y., Li Y.X. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019; 20(3): 352–60. doi:10.1016/S1470-2045(18)30813-1.; Marta G.N., Coles C., Kaidar-Person O., Meattini I., Hijal T., Zissiadis Y., Pignol J.P., Ramiah D., Ho A.Y., Cheng S.H., Sancho G., Offersen B.V., Poortmans P. The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: A critical review. Crit Rev Oncol Hematol. 2020; 156. doi:10.1016/j.critrevonc.2020.103090.; Ricci J.A., Epstein S., Momoh A.O., Lin S.J., Singhal D., Lee B.T. A meta-analysis of implant-based breast reconstruction and timing of adjuvant radiation therapy. J Surg Res. 2017; 218: 108–16. doi:10.1016/j.jss.2017.05.072.; https://www.siboncoj.ru/jour/article/view/3350
-
2Academic Journal
Source: Ukrainian Neurosurgical Journal; Vol. 29 No. 1 (2023); 38-47
Ukrainian Neurosurgical Journal; Том 29 № 1 (2023); 38-47Subject Terms: radiation dose hypofractionation, лучевая терапия, новообразование, neoplasms, glioblastoma, 3. Good health, survival analysis, глиобластома, гліобластома, анализ выживаемости, гіпофракціонування, гипофракционирование, аналіз виживаності, променева терапія, radiotherapy, новоутворення
File Description: application/pdf
Access URL: http://theunj.org/article/view/270580
-
3Academic Journal
Authors: V. P. Sokurenko, A. V. Karpenko, T. A. Lushchaeva, T. E. Ponezha, В. П. Сокуренко, А. В. Карпенко, Т. А. Лущаева, Т. Е. Понежа
Source: Diagnostic radiology and radiotherapy; Том 13, № 4 (2022); 115-123 ; Лучевая диагностика и терапия; Том 13, № 4 (2022); 115-123 ; 2079-5343
Subject Terms: гипофракционирование, radiation therapy, hypofractionation, лучевая терапия
File Description: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/811/581; Harris J.P., Chen M.M, Oroscet R.K et al. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer // JAMA Otolaryngol Head Neck Surg. 2018. Vol. 144, Nо. 4. P. 349–359. doi:10.1001/jamaoto.2017.3406.; Mitra S., Simson D.K., KhuranaН. et al. Treatment delay during radiotherapy of cancer patients due to COVID-19 pandemic // Asian Pac. J. Cancer Prev. July 2022. Vol. 23, Issue 7. Р. 2415–2420. doi:10.31557/APJCP.2022.23.7.2415.; Graboyes E.M., Kompelli A.R., Neskey D.M. et al. Association of treatment delays with survival for patients with head and neck cancer // JAMA Otolaryngol Head Neck Surg. 2019. Vol. 145, Nо. 2. P. 166–177. doi:10.1001/jamaoto.2018.2716.; Shin J.Y., Yoon J.K., Shin A.K. et al. Locoregionally advanced oral cavity cancer: A propensity-score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy // Head&Neck. 2018. Vol. 40, Issue 9. P. 1934–1946. doi:10.1002/hed.25185.; Moore E.J., van Abel K.M., Price D.L., Lohse Ch.M. et al. Transoral robotic surgery for oropharyngeal carcinoma: Surgical margins and oncologic outcomes // Head&Neck. 2018. Vol. 40, Issue 4. P. 747–755. doi:10.1002/hed.25055.; Loganadane G., Kann B.H. et al. Clinical outcomes of head and neck cancer patients who undergo resection, but forgo adjuvant therapy // Anticancer Research. 2019. Vol. 39, Nо. 9. Р. 4885–4890. doi: https://doi.org/10.21873/anticanres.13674.; Ang К.К., Trotti А., Brown B.W. et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer // Int. J. of RO&Biology&Physics. 2001. Vol. 51, Issue 3. P. 571–578. doi:10.1016/S0360-3016(01)01690-X.; Piras А., Venuti V., et al. Covid-19 and radiotherapy: a systematic review after 2 years of pandemic // Clinical and Translational Imaging. 2022. July. P. 612–629. doi:10.1007/s40336-022-00513-9.; Karpenko A.V., Sibgatullin R.R., Boyko A.A., Nikolayeva O.M. Rapid clinical progression of stage III–IV oral and oropharyngeal cancer after upfront surgery and difficulty in the assessment of the effectiveness of adjuvant radiotherapy // Head and Neck Tumors (HNT). 2022. Vol. 12, No. 2. Р. 25–32. (In Russ.) doi:10.17650/2222-1468-2022-12-2-25-32.; Graboyes Е.М., Garrett-Mayer Е., Ellis M.A., Sharma A.K., Wahlquist A.E., Lentsch E.J., Nussenbaum B., Day T.A. Effect of time to initiation of postoperative radiation therapy on survival in surgically-managed head and neck cancer // Cancer. December 2017. Vol. 123, Issue 24. P. 4841–4850. doi:10.1002/cncr.30939.; Mackillop W.J., Bates J.H., O’Sullivan B., Withers H.R. The effect of delay in treatment on local control by radiotherapy // Int. J. Radiat. Oncol. Biol. Phys. 1996. Vol. 34. No. 1. P. 43–50. doi:10.1016/0360-3016(95)02049-7.; Huang J., Barbera L., Brouwers M., et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review // J. Clin. Oncol. 2003. Vol. 21. № 3. P. 555–563. doi:10.1200/JCO.2003.04.171.; Levy D.A., Li H., Sterba K.R. et al. Development and validation of nomograms for predicting delayed postoperative radiotherapy initiation in head and neck squamous Cell carcinoma // JAMA Otolaryngol Head Neck Surg. 2020. Vol. 146, No. 5. P. 455–464. doi:10.1001/jamaoto.2020.0222.; Ho A.S., Kim S., Tighiouart М. et al. Quantitative survival impact of composite treatment delays in head and neck cancer // Cancer. 2018. Vol. 124. No. 15. P. 3154–3162. doi:10.1002/cncr.31533.; Al-Dweri F.M., Guirado D., Lallena A.M., Pedraza V. Effect on tumour control of time interval between surgery and postoperative radiotherapy: an empirical approach using Monte Carlo simulation // Phys. Med. Biol. 2004.Vol. 49, No. 13. P. 2827–2839. doi:10.1088/0031-9155/49/13/005.; Steel G. Basic clinical radiobiology. New York: Oxford University Press, 1997. P. 78–92.; Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 56, Nо. 2. P. 399–412. doi:10.1016/s0360-3016(02)04469-3.; Nagar H., Formenti S.C. Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy // Nature Reviews Clinical Oncology. April 2020. Vol. 17. P. 332–334. doi:10.1038/s41571-020-0375-1.; Fujiwara R.J.T., Judson B.L., Yarbrough W.G., Husain Z., Mehra S. Treatment delays in oral cavity squamous cell carcinoma and association with survival // Head & Neck. 2017. Vol. 39. No. 4. P. 639–646. doi:10.1002/hed.24608.; Liederbach Е. et al. Impact of delays to adjuvant radiation therapy on survival in squamous Cell carcinoma of the oral cavity and oropharynx // Oncology. 2020. Vol. 29, Nо. 4, No. 4, Suppl. 1.; Ferreira J.A.G., Olasolo J.J., Azinovic I., Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature // Reports of Practical Oncology & Radiotherapy. 2015. Vol. 20, No. 5. P. 328–339. doi:10.1016/j.rpor.2015.05.010.; Schiff P.B., Harrison L.B., Strong E.W. et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer // J. Surg. Oncol. 1990. Vol. 43, Nо. 4. P. 203–208. doi:10.1002/jso.2930430403.; Maghami Е., Sh.A Koyfman, J. Weiss. Personalizing postoperative treatment of head and neck cancers // Am. Soc. Clin. Oncol. Educ. Book. May 2018. Vol. 38. P. 515–522. doi:10.1200/EDBK_201087.; Divi V., Chen M., Porter J., et al. Reducing the time from surgery to adjuvant radiation therapy: an institutional quality improvement project // Otolaryngol Head Neck Surg. July 2018. Vol. 159, Nо. 1. P. 158–165. doi:10.1177/0194599818768254.; Guttmann D.M., Kobie J., Grover S., Lin А., Lukens J.N. et al. National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival // Head & Neck. 2018. Vol. 40, Nо. 6. P. 1147–1155. doi:10.1002/hed.25091.; Snow A.N., Anderson C.M., Watkins J.M., et al. Impact of treatment time on outcome for resected head and neck squamous cell carcinoma by HPV Status // Clinical Oncology and Research Journal. February 2020. doi:10.31487/j.COR.2020.02.09.; Marwah R., Goonetilleke D., Smith J., Chilkuri M. Evaluating delays in patients treated with post-operative radiation therapy for head and neck squamous cell carcinoma // Radiation Oncology. 2022. Vol. 66, No. 6. P. 840–846. doi:10.1111/1754-9485.13449.; Dale R.G., Hendry J.H., Jones B., et al. Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedule // Clin. Oncol. 2002. Vol. 14, Nо. 5. P. 382–393. doi:10.1053/clon.2002.0111.; Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 // International Journal of Radiation Oncology, Biology, Physics. 2000. Vol. 48, №. 1. P. 7–16. DOI:10.1016/s0360-3016(00)00663-5.; Fowler J.F. Is there an optimum overall time for head and neck radiotherapy? A review, with new modeling // Clin. Oncol. 2007. Vol. 19, Nо. 1. P. 8–22. doi:10.1016/j.clon.2006.09.008.; Huang Sh.H., O’Sullivan B., Ringash J.,et al. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal // Cancer. 2020. Vol. 126, Nо. 15. P. 3426–3437. doi:10.1002/cncr.32968; Thomson D.J., Palma D., Guckenberger M., et al. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement // Int. J. Radiat. Oncol. Biol. Phys. 2020. Vol. 107, Nо. 4. Р. 618–627. doi:10.1016/j.ijrobp.2020.04.016.; ClinicalTrials.gov Identifier: NCT05120947 https://clinicaltrials.gov/ct2/show/NCT05120947 (дата обращения 22.10.2022).
-
4Academic Journal
Authors: A. S. Tokarev, O. L. Evdokimova, V. A. Rak, O. A. Viktorova, А. С. Токарев, О. Л. Евдокимова, В. А. Рак, О. А. Викторова
Source: Diagnostic radiology and radiotherapy; Том 11, № 3 (2020); 104-110 ; Лучевая диагностика и терапия; Том 11, № 3 (2020); 104-110 ; 2079-5343 ; 10.22328/2079-5343-2020-3
Subject Terms: метастазы рака яичников в головной мозг, hypofractionation, ovarian cancer brain metastases, гипофракционирование
File Description: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/553/435; Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников // Практическая онкология. 2000. Т. 1, № 4. С. 7–13.; Жорданиа К.И., Паяниди Ю.Г., Калиничева Е.В. Два пути развития серозного рака яичников // Онкогинекология. 2014. № 3. С. 42–48.; Morgan R.J., Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N., Behbakht K., Chen L.M. et al. Ovarian Cancer, Version 1.2016, NCCN clinical practice guidelines in oncology // J. Natl. Compr. Canc. Netw. 2016. Vol. 14, No. 9. P. 1134–1163. doi:10.6004/jnccn.2016.0122.; Cohen Z.R., Suki D., Weinberg J.S. Marmor E., Lang F.F., Gershenson D.M., Sawaya R. Brain metastases in patients with ovarian carcinoma: prognostic factors and out-come // J. Neurooncol. 2004. Vol. 66 (3). Р. 313–325. PMID: 15015663.; Cormio G., Maneo A., Parma G., Pittelli M.R., Miceli M.D., Bonazzi C. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review // Ann. Oncol. 1995. Vol. 6, No 6. P. 571–574. doi:10.1093/oxfordjournals.annonc.a059246.; Koul A., Loman N., Malander S., Borg A., Ridderheim M. Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report // Gynecol. Oncol. 2001. Vol. 80, No. 3. P. 399–402. doi:10.1006/gyno.2000.6085.; Anupol N., Ghamande S., Odunsi K., Driscoll D., Lele S. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases // Gynecol. Oncol. 2002; Vol.85, 3. P.487–492. doi:10.1006/gyno.2002.6653.; Chen Y.L., Cheng W.F., Hsieh C.Y., Chen C.A. Brain metastasis as a late manifestation of ovarian carcinoma // Eur. J. Canc. Care (Engl). 2011; Vol. 20, 1. P.44–49. DOI:10.1111/j.1365–2354.2009.01133.x.; Niranjan A., Lunsford L.D., Kano H. eds. Leksell Radiosurgery. Guidelines for Multiple Brain Metastases Radiosurgery. Prog Neurol Surg. Basel, Karger. 2019; Vol. 34. P. 100–109. DOI:10.1159/000493055.; Gadducci A., Tana R., Teti G., Fanucchi A., Pasqualetti F., Cionini L., Genazzani A.R. Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature // Anticancer. Res. 2007; Vol. 27, 6C. P.4403–4409.; Geisler J.P., Geisler H.E. Brain metastases in epithelial ovarian carcinoma // Gynecol. Oncol. 1995. Vol. 57, No. 2. P. 246–249. doi:10.1006/gyno.1995.1134.; Kolomainen D.F., Larkin J.M., Badran M., A’Hern R.P., King D.M., Fisher C., Bridges J.E., Blake P.R., Barton D.P., Shepherd J.H., Kaye S.B., Gore M.E. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence // J. Clin. Oncol. 2002; Vol. 20, No. 4. P. 982–986. doi:10.1200/JCO.2002.20.4.982.; Andrews D.W., Scott C.B., Sperduto P.W. Flanders A.E., Gaspar L.E., Schell M.C., Werner-Wasik M., Demas W., Ryu J., Bahary J.P., Souhami L., Rotman M., Mehta M.P., Curran WJ. Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase EH results of the RTOG 9508 randomised trial // Lancet. 2004. Vol. 363, No. 9422. P. 1665–1672. doi:10.1016/S0140-6736(04)16250-8.; Pietzner K., Oskay-Oezcelik G., El Khalfaoui K., Boehmer D., Lichtenegger W., Sehouli J. Brain Metastases from Epithelial Ovarian Cancer: Overview and Optimal Management // Anticancer Res. 2009. Vol. 29, No. 7. P. 2793–2798.; Vlasveld L.T., Beynen J.H., Boogerd W., Ten Bokkel Huinink W.W., Rodenhuis S. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study // Cancer Chemother. Pharmacol. 1990. Vol. 25, No. 5. P. 382–383. doi:10.1007/bf00686244.; Plaxe S.C., Dottino P.R., Goodman H.M., Deligdisch L., Idelson M., Cohen C.J. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy // Gynecol. Oncol. 1990. Vol. 37, No. 2. P. 244–249. doi:10.1016/0090.8258(90)90341-h.; Pectasides D., Pectasides M., Economopoulos T. Brain metastases from epithelial ovarian cancer: a review of the literature // Oncologist. 2006. Vol. 11, No. 3. P. 252–260. doi:10.1634/theoncologist.11.3-252; Rodriguez G.C., Soper J.T., Berchuck A., Oleson J., Dodge R., Montana G., Clarke-Pearson D.L. Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery // J. Clin. Oncol. 1992. Vol. 10, No. 10. P. 1553–1560. doi:10.1200/JCO.1992.10.10.1553; Cohen Z.R., Suki D., Weinberg J.S., Marmor E., Lang F.F., Gershenson D.M., Sawaya R. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome // J. Neurooncol. 2004. Vol. 66, No. 3. P. 313–325. doi:10.1023/b:neon.0000014516.04943.38; Pakneshan S., Safarpour D., Tavassoli F., Jabbari B. Brain metastasis from ovarian cancer: a systematic review // J. Neurooncol. 2014. Vol. 119, No. 1. P. 1–6. doi:10.1007/s11060-014-1447-9.; Boyd T.S, Mehta M.P. Stereotactic radiosurgery for brain metastases // Oncology (Williston Park). 1999. Vol. 13, No. 10. P. 1397–1409.; Aoyama H., Shirato H., Onimaru R., Kagei K., Ikeda J., Ishii N., Sawamura Y., Miyasaka K. Hypofractionated stereotactic radiotherapy alone without wholebrain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 56, No. 3. P. 793–800. doi:10.1016/s0360-3016(03)00014-2.; Higuchi Y., Serizawa T., Nagano O., Matsuda S., Ono J., Sato M., Iwadate Y., Saeki N. Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 74, No. 5. P. 1543–1548. doi:10.1016/j.ijrobp.2008.10.035.; Song C.W., Cho L.C., Yuan J., Dusenbery K.E., Griffin R.J., Levitt S.H. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model // Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 87, No. 1. P. 18–19. doi:10.1016/j.ijrobp.2013.03.013.
-
5Academic Journal
Authors: N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, T. N. Borisova, M. S. Ardzinba, A. A. Fedorova, P. V. Murashova, Н. В. Мариниченко, К. К. Лактионов, А. В. Назаренко, Т. Н. Борисова, М. С. Ардзинба, А. А. Федорова, П. В. Мурашова
Source: Meditsinskiy sovet = Medical Council; № 9 (2020); 271-276 ; Медицинский Совет; № 9 (2020); 271-276 ; 2658-5790 ; 2079-701X
Subject Terms: пульмонит, chemoradiotherapy, local dose escalation, hypofractionation, pulmonitis, химиолучевая терапия, локальная эскалация дозы, гипофракционирование
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5745/5243; Tessen H.W., Hutzschenreuter U., Steffens C.C., Nusch A., Spirik J., Marschner N. The treatment of lung cancer in German outpatient centres. Data from a clinical registry – TLK Registry. Onkologie. 2011;34 (Suppl. 6) (Poster P533):153. Available at: https://www.karger.com/Article/Pdf/333301.; Howlader N., Noone A.M., Krapcho M., Miller D., Bishop K., Kosary C.L. et al. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD; 2013. Vol 20, 2015 p. Available at: http://seer.cancer.gov/csr/1975_2010.; Wakelee H., Kelly K., Edelman M.J. 50 Years of Progressin the Systemic Therapy of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2014;34:177–189. doi:10.14694/EdBook_AM.2014.34.177.; Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899–909. doi:10.1136/bmj.311.7010.899.; Aupérin A., Le Péchoux C., Rolland E., Curran W.J., Furuse K., Fournel P. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190. doi:10.1200/JCO.2009.26.2543.; O’Rourke N., Roqué I., Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;(6):50–53. doi:10.1002/14651858.CD002140.pub3.; Сhen C.P., Weinberg V.K., Jahan T.M., Jablons D.M., Yom S.S. Implication of delayed initiation of radiotherapy accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. Thorac. Oncol. 2011;6(11):1857–1864. doi:10.1097/JTO.0b013e318229a41e.; Machtay M., Bae K., Movsas B., Paulus R., Gore E.M., Komaki R. et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425–434. doi:10.1016/j.ijrobp.2010.09.004.; Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;2(16):187–199. doi:10.1016/S1470-2045(14)71207-0.; Dess R.T., Sun Y., Matuszak M.M., Sun G., Soni P.D., Bazzi L. et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35(13):1395–1402. doi:10.1200/JCO.2016.71.6142.; Семищева Н.Л., Карапетян Е.И., Мальцева Т.А., Авдеева Н.В., Одиреев А.Н. Постлучевой пневмонит в практике пульмонолога. Бюллетень физиологии и патологии дыхания. 2014;(53):137–142. Режим доступа: https:// cfpd.elpub.ru/jour/article/view/733. Semishcheva N.L., Karapetian E.I., Maltseva T.A., Avdeeva N.V., Odireev A.N. Postradiation pneumonitis in the practice of a pulmonologist. Byulleten fiziologii i patologii dykhaniya = Bulletin Physiology and Pathology of Respiration. 2014;(53):137–142. (In Russ.) Available at: https://cfpd.elpub.ru/jour/article/view/733.; Turner L.M., Howard J.A., Dehghanpour P., Barrett R.D., Rebueno N., Palmer M. et al. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim. 2011;4(36):383–388. doi:10.1016/j.meddos.2010.09.007.; Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76(4):593–601. doi:10.1002/1097-0142(19950815)76:43.0.co;2-n.; Aupérin A., Pechoux C.L., Pignon J.P., Koning C., Jeremic B., Glamon G. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-smallcell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17(3):473–483. doi:10.1093/annonc/mdj117.; Деньгина Н.В. Оптимальные схемы химиолучевого лечения немелкоклеточного рака легкого III стадии (обзор литературы). Поволжский онкологический вестник. 2015;(2):74–79. Режим доступа: http:// oncovestnik.ru/index.php/khimioterapiya/item/994-optimalnye-skhemykhimioluchevogo-lecheniya-nemelkokletochnogo-raka-legkogo-iii-stadiiobzor-literatury. Dengina N.V. Optimal regimens for chemoradiotherapy of stage III nonsmall cell lung cancer (literature review). Povolzhskiy onkologicheskiy vestnik = Oncology Bulletin of the Volga Region. 2015(2):74–79. (In Russ.) Available at: http://oncovestnik.ru/index.php/khimioterapiya/item/994-optimalnye-skhemy-khimioluchevogo-lecheniya-nemelkokletochnogoraka-legkogo-iii-stadii-obzor-literatury.
-
6Academic Journal
Authors: Батян, А.Н., Гончарова, Е.В., Гайда, А.В., Демешко, П.Д., Лемешевскии, В.О., Оргиш, А.Н., Петкевич, М.Н., Batyan, А.N., Hancharova, К.V., Haida, А.V., Dziameshka, Р.D., Lemiasheuski, V.О., Orgish, А.N., Piatkevich, М.N.
Subject Terms: радиобиология, радиобиологические модели, линейно-квадратичная модель, радиочувствительность, гипофракционирование, лучевая терапия, перерывы в лечении, веб-приложение, radioblology, radioblological models, linear-qиadratic mоdеl, radioseпsitivity, hypofractionation, breast саnсеr, radiotherapy, treatmeпt iпterruptioпs, Web applicatioп
File Description: application/pdf
Availability: https://rep.polessu.by/handle/123456789/32416
-
7Academic Journal
Authors: D. V. Gogolin, I. A. Gulidov, K. E. Medvedeva, Y. A. Ragulin, Y. S. Mardinsky, I. N. Ivanova, L. V. Kursova, I. I. Kotuhov, A. Y. Buksha, Д. В. Гоголин, И. А. Гулидов, К. Е. Медведева, Ю. А. Рагулин, Ю. С. Мардынский, И. Н. Иванова, Л. В. Курсова, И. И. Котухов, А. Ю. Букша
Contributors: This study was carried out within the framework of the state task of the A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation for 2015–2016 and the first half of 2017 10 ., Данная работа проводилась в рамках выполнения тем государственного задания МРНЦ им. А.Ф. Цыба – филиала ФГБУ «НМИЦ Радиологии» Минздрава России за 2015–2016 гг. и первую половину 2017 г. 10 .
Source: Siberian journal of oncology; Том 18, № 4 (2019); 21-26 ; Сибирский онкологический журнал; Том 18, № 4 (2019); 21-26 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-4
Subject Terms: выживаемость, radiation therapy, hyperfractionated radiotherapy, hypofractionated radiotherapy, survival, лучевая терапия, гипофракционирование, гиперфракционирование
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1137/648; Трахтенберг А.Х., Франк Г.А., Колбанов К.И., Седых С.А., Пикин О.В. Опухоли легких. Руководство по онкологии. М., 2008. 326.; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М., 2017. 250.; Ramroth J., Cutter D.J., Darby S.C., Higgins G.S., McGale P., Partridge M., Taylor C.W. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4): 736–747. doi:10.1016/j.ijrobp.2016.07.022.; O’Rourke N., Roqué I., Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010 Jun 16; (6): CD002140. doi:10.1002/14651858. CD002140.pub3.; Rodrigues G., Choy H., Bradley J., Rosenzweig K.E., Bogart J., Curran W.J.Jr., Gore E., Langer C., Louie A.V., Lutz S., Machtay M., Puri V., Werner-Wasik M., Videtic G.M. Definitive radiotherapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015 May-Jun; 5(3): 141–8. doi:10.1016/j. prro.2015.02.012.; Мардынский Ю.С., Гулидов И.А., Иванова И.Н., Курсова Л.В., Золотков А.Г., Кудрявцев Д.В., Рагулин Ю.А., Гоголин Д.В. Результаты применения режима ускоренного гиперфракционирования в лечении немелкоклеточного рака легкого. Сибирский онкологический журнал. 2010; 2: 11–14.; Westover K.D., Loo B.W.Jr., Gerber D.E., Iyengar P., Choy H., Diehn M., Hughes R., Schiller J., Dowell J., Wardak Z., Sher D., Christie A., Xie X.J., Corona I., Sharma A., Wadsworth M.E., Timmerman R. Precision Hypofractionated Radiation Therapy in poor perfoming patients with NCSLC: phase I dose escalation trial. Int J Radiat Oncol Biol Phys. 2015 Sep 1; 93(1): 72–81. doi:10.1016/j.ijrobp.2015.05.004.; Bearz A., Minatel E., Rumeileh I.A., Borsatti E., Talamini R., Franchin G., Gobitti C., Del Conte A., Trovò M., Baresic T. Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractioneted regimen. BMC Cancer. 2013 Oct 31; 13: 513. doi:10.1186/1471- 2407-13-513.; Ильин М.А., Барышникова Д.В., Ядыков О.А., Ивашин А.В., Сотников В.М., Паньшин Г.А., Котляров П.М., Харченко В.П., Солодкий В.А., Гваришвили А.А. Результаты лучевой терапии периферического рака легкого с эскалацией дозы. Вестник Российского научного центра рентгенорадиологии Минздрава России. 2012; 4(12).; Каприн А.Д., Галкин В.Н., Жаворонков Л.П., Иванов В.К., Иванов С.А., Романко Ю.С. Синтез фундаментальных и прикладных исследований – основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017; 26(2): 26–40.; https://www.siboncoj.ru/jour/article/view/1137
-
8Academic Journal
Authors: Артюх, С. В., Artiukh, S. V.
Subject Terms: рак голови та шиї, хрономодульована терапія, гіпофракціонування, хіміопроменеве лікування, променева токсичність, рак головы и шеи, хрономодулированная терапия, гипофракционирование, химиолучевое лечение, лучевая токсичность, head and neck cancer, chronomodulated therapy, hypofraction, chemoradiotherapy, radiation toxicity, 616.22–006.61–08-039.76–059 +615.849.114
File Description: application/pdf
Relation: Артюх С. В. Порівняльний аналіз ефективності різних схем хіміомодифікації променевої терапії у хворих на місцевопоширений рак голови та шиї / С. В. Артюх // Вісник проблем біології і медицини. – 2018. – Вип. 2 (144). – С. 131–135.; https://repository.pdmu.edu.ua/handle/123456789/16142
-
9Academic Journal
Authors: G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin, Г. В. Афонин, Ю. А. Рагулин, М. В. Авксентьева, И. А. Гулидов, С. А. Иванов, А. Д. Каприн
Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 11, No 2 (2018); 3-8 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 11, No 2 (2018); 3-8 ; 2070-4933 ; 2070-4909
Subject Terms: оценка стоимости, hypofractionation, radiation therapy, economic evaluation, cost estimation, гипофракционирование, лучевая терапия, экономический анализ
File Description: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/255/247; Состояние онкологической помощи населению России в 2016 г. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М. 2017; 236 с.; Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S. et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010 Feb 11; 362 (6): 513-20. DOI:10.1056/NEJMoa0906260.; Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J., Barrett-Lee P.J., et.al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct; 14 (11): 1086-94. DOI:10.1016/S14702045(13)70386-3. Epub 2013 Sep 19.; Hickey B.E., James M.L., Lehman M., Hider P.N., Francis D.P., et al. Hypofractionated radiation therapy for early breast cancer. Cochrane Database Syst Rev. 2016 Jul 18; 7: CD003860. DOI:10.1002 / 14651858.CD003860.pub4.; Rudat V., Nour A., Hammoud M. et al. Better compliance with hypofractionation vs. conventional fractionation in adjuvant breast cancer radiotherapy. Strahlenther Onkol. 2017; 193(5): 375-384. Published online 2017 Feb 23. DOI:10.1007/s00066-017-1115-z.; Mortimer J.W., McLachlan C.S., Hansen C.J., Assareh H., Last A., McKay M.J., et al. Use of hypofractionated post-mastectomy radiotherapy reduces health costs by over $2000 per patient: An Australian perspective. J Med Imaging Radiat Oncol. 2016 Feb; 60 (1): 146-53. DOI:10.1111/1754-9485.12405. Epub 2015 Oct 29.; Suh W.W., Pierce L.J., Vicini F.A., Hayman J.A. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005 Jul 1; 62 (3): 790-6. DOI:10.1016/j. ijrobp.2004.10.039.; https://www.pharmacoeconomics.ru/jour/article/view/255
-
10Academic Journal
Authors: N. A. Vorobyov, N. I. Martynova, A. V. Mikhailov, Yu. V. Gutsalo, A. V. Kubasov, Н. А. Воробьев, Н. И. Мартынова, А. В. Михайлов, Ю. В. Гуцало, А. В. Кубасов
Source: Cancer Urology; Том 14, № 2 (2018); 122-129 ; Онкоурология; Том 14, № 2 (2018); 122-129 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-2
Subject Terms: радиохирургия, stereotactic radiotherapy, hypofractionation, CyberKnife, radiosurgery, стереотаксическая лучевая терапия, гипофракционирование, кибернож
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/821/771; WHO Cancer Registry. Prostate cancer estimated incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.; Ogawa K., Nakamura K., Sasaki T. et al. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: changing trends in the patterns of care process survey. Int J Radiat Oncol Biol Phys 2011;81(5):1310–8. DOI:10.1016/j.ijrobp.2010.08.014. PMID: 20950959.; Pedicini P., Strigari L., Benassi M. Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2013;85(5):e231–7. DOI:10.1016/j. ijrobp.2012.11.033. PMID: 23332226.; Fowler J.F., Ritter M.A., Chappell R.J., Brenner D.J. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56(4):1093–104. DOI:10.1016/S0360-3016(03)00132-9. PMID: 12829147.; Zaorsky N.G., Palmer J.D., Hurwitz M.D. et al. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 2015;115(3):295–300. DOI:10.1016/j.radonc.2015.05.011. PMID: 26028229.; Hegemann N.S., Guckenberger M., Belka C. et al. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol 2014;9:275–90. DOI:10.1186/s13014014-0275-6. PMID: 25480014.; Mohler J.L., Kantoff P.W., Armstrong A.J. et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014;12(5):686– 718. DOI:10.6004/jnccn.2014.0072. PMID: 24812137.; http://www.urospec.com/uro/Forms/ipss.pdf.; Timmerman R.D. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 2008;18(4):215–22. DOI:10.1016/j.semradonc.2008.04.001. PMID: 18725106.; Roach M. 3rd, Hanks G., Thames H. Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65(4):965–74. DOI:10.1016/j.ijrobp.2006.04.029. PMID: 16798415.; Patel C., Elshaikh M.A., Angermeier K. et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004;63(1):110–3. DOI:10.1016/j.urology.2003.08.025. PMID: 14751360.; Ray M.E., Thames H.D., Levy L.B. et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64(4):1140–50. DOI:10.1016/j. ijrobp.2005.07.006. PMID: 16198506.; Stock R.G., Klein T.J., Cesaretti J.A., Stone N.N. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009;74(3):753–8. DOI:10.1016/j. ijrobp.2008.08.049. PMID: 19084351.; Kupelian P.A., Potters L., Khuntia D. et al. Radical prostatectomy, external beam radiotherapy or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58(1):25–33. DOI:10.1016/S0360-3016(03)00784-3. PMID: 14697417.; Kotecha R., Yamada Y., Pei X. et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013;12(1):44–9. DOI:10.1016/j.brachy.2012.05.003. PMID: 22831750.; Smith G., Pickles T., Crook J. et al. Brachytherapy improves biochemical failure-free survival in lowand intermediaterisk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Int J Radiat Oncol Biol Phys 2015;91(3):505–16. DOI:10.1016/j. ijrobp.2014.11.018. PMID: 25596107.; Katz A.J., Santoro M., Diblasio F., Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013;8(1):118. DOI:10.1186/1748-717X-8-118. PMID: 23668632.; Katz A.J., Santoro M., Ashley R. et al. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010;9(6):575–82. DOI:10.1177/153303461000900605. PMID: 21070079.; Peeters S.T., Heemsbergen W.D., Koper Р.С.М. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990–6. DOI:10.1200/JCO.2005.05.2530. PMID: 16648499.; Dearnley D.P., Sydes M.R., Graham J.D. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol 200;8(6):475–87. DOI:10.1016/S1470-2045(07)70143-2. PMID: 17482880.; Martin J.M., Rosewall T., Bayley A. et al. Phase II trial of hypofractionated imageguided intensity modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69(4):1084–9. DOI:10.1016/j.ijrobp.2007.04.049. PMID: 17606331.; Zietman A.L., Bae K., Slater J.D. et al. Randomized trial comparing conventionaldose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28(7):1106–11. DOI:10.1200/JCO.2009.25.8475. PMID: 20124169.; Lock M., Best L., Wong E et al. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;80(5):1306–15. DOI:10.1016/j.ijrobp.2010.04.054. PMID: 20708855.; Meier R., Beckman A., Henning G. et al. Five-year outcomes from a multicenter trial of stereotactic body radiation therapy for lowand intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2015;93(3):s199. DOI:10.1016/j.ijrobp.2015.07.477.; https://oncourology.abvpress.ru/oncur/article/view/821
-
11Academic Journal
Source: Патология кровообращения и кардиохирургия, Vol 16, Iss 3, Pp 61-66 (2015)
Subject Terms: СТЕРЕОТАКСИЧЕСКАЯ КОНФОРМНАЯ ЛУЧЕВАЯ ТЕРАПИЯ, ГИПОФРАКЦИОНИРОВАНИЕ, РАДИОХИРУРГИЯ, DOSE ESCALATION, DOSE TO NORMAL TISSUE, Surgery, RD1-811
File Description: electronic resource
-
12Academic Journal
Authors: V. A. Solodkiy, G. A. Panshin, N. V. Kharchenko, Z. S. Tsallagova, S. M. Milyukov, T. R. Izmailov, В. А. Солодкий, Г. А. Паньшин, Н. В. Харченко, З. С. Цаллагова, С. М. Милюков, Т. Р. Измайлов
Source: Siberian journal of oncology; Том 16, № 4 (2017); 11-18 ; Сибирский онкологический журнал; Том 16, № 4 (2017); 11-18 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-16-4
Subject Terms: гипофракционирование, model of TDF (time–dose–fractionation), linear-quadratic model (LQ-model), α/β ratio, hypofractionated radiotherapy, модель время–доза–фракционирование (ВДФ), линейно-квадратичная модель (ЛКМ), α/β
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/564/453; Милюков С.М. Диагностика и лечение инфильтративных глиом низкой степени злокачественности (обзор литературы). Вестник Российского научного центра рентгенорадиологии. 2016; 16 (2). URL: http://vestnik.rncrr.ru/vestnik/v16/v16.htm (дата обращения 05.05.2016).; Милюков С.М., Паньшин Г.А., Харченко Н.В., Цаллагова З.С., Шишкина Л.В., Кунда М.А., Запиров Г.М., Измайлов Т.Р. Многофакторный анализ наиболее значимых параметров и факторов радиотерапии супратенториальных инфильтративных глиом низкой степени злокачественности. Трудный пациент. 2016; 14 (1): 25–28.; Милюков С.М., Харченко Н.В., Кунда М.А., Цаллагова З.С., Запиров Г.М., Моргунов А.А., Измайлов Т.Р. Влияние лучевой терапии на результаты комплексного лечения внутримозговых супратенториальных инфильтративных глиом низкой степени злокачественности (Grade II) у взрослых. Вестник Российского университета дружбы народов. Серия: Медицина. 2015; 4: 55–61.; National Comprehensive Cancer Network Guidelines. URL: http:// www.nccn.org/professionals/physician_gls/pdf/cns.pdf (дата обращения 05.05.2016).; Абсалямова О.В., Аникеева О.Ю., Голанов А.В., Кобяков Г.Л., Коновалов А.Н., Корниенко В.Н., Рыжова М.В. Клинические рекомендации по лечению первичных опухолей центральной нервной системы. 2013.; Кобяков Г.Л., Абсалямова О.В., Аникеева О.Ю., Бекяшев А.Х., Голанов А.В., Коновалов А.Н., Кривошапкин А.Л., Олюшин В.Е., Потапов А.А., Пронин И.Н., Рыжова М.В., Смолин А.В., Таняшин С.В., Трунин Ю.Ю., Улитин А.Ю., Шишкина Л.В. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системы. Злокачественные опухоли. 2015; 4 (Спецвыпуск): 55–79. doi:10.18027/2224-5057-2015-4s-55-79.; Амиралиев А.М., Багрова С.Г., Бойко А.В., Болотина Л.В., Борисова Т.Н., Бредер В.В., Коломейцева А.А. Клинические рекомендации по диагностике и лечению больных с первичными опухолями головного мозга. 2014.; Soffietti R., Baumert B.G., Bello L., Deimling A., Duffau H., Frenay M., Grisold W., Grant R., Graus F., Hoang-Xuan K., Klein M., Melin B., Rees J., Siegal T., Smits A., Stupp R., Wick W. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010 Sep; 17 (9): 1124–33. doi:10.1111/j.1468-1331.2010.03151.x.; Stupp R., Brada M., van den Bent M.J., Tonn J.C., Pentheroudakis G.; ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep; 25 Suppl 3: iii93–101. doi:10.1093/annonc/mdu050.; Van den Bent M.J., Afra D., de Witte O., Ben Hassel M., Schraub S., Hoang-Xuan K., Malmström P.O., Collette L., Piérart M., Mirimanoff R., Karim A.B.; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORT 22845 randomised trial. Lancet. 2005 Sep 17–23; 366 (9490): 985–90.; Karim A.B., Maat B., Hatlevoll R., Menten J., Rutten E.H., Thomas D.G., Mascarenhas F., Horiot J.C., Parvinen L.M., van Reijn M., Jager J.J., Fabrini M.G., van Alphen A.M., Hamers H.P., Gaspar L., Noordman E., Pierart M., van Glabbeke M. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996 Oct 1; 36 (3): 549–56.; Shaw E., Arusell R., Scheithauer B., O’Fallon J., O’Neill B., Dinapoli R., Nelson D., Earle J., Jones C., Cascino T., Nichols D., Ivnik R., Hellman R., Curran W., Abrams R. Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002 May 1; 20 (9): 2267–76.; Prabhu V.C., Khaldi A., Barton K.P., Melian E., Schneck M.J., Primeau M.J., Lee J.M. Management of diffuse low-grade cerebral gliomas. Neurol Clin. 2010 Nov; 28 (4): 1037–59. doi:10.1016/j.ncl.2010.03.022.; Солодкий В.А., Паньшин Г.А., Харченко Н.В., Милюков С.М., Измайлов Т.Р. Прогностические факторы при лечении супратенториальных инфильтративных глиом головного мозга низкой степени злокачественности. Вопросы онкологии. 2016; 62 (5): 643–648.; Измайлов Т.Р., Паньшин Г.А., Милюков С.М., Даценко П.В. Оценка эффективности лучевой терапии глиом высокой степени злокачественности на основе модели ВДФ (время–доза-фракционирование). Вопросы онкологии. 2013; 59 (5): 629–635.; Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989 Aug; 62 (740): 679–94.; Milyukov S., Lysak Yu., Panshin G., Kharchenko N., Golub S., Izmailov T. Clinical radiobiology of infiltrative low grade gliomas (grade II). Fourth International Conference on Radiation and Applications in Various Fields of Research. Book of abstracts. Niš. 2016; 361.; Pedicini P., Fiorentino A., Simeon V., Tini P., Chiumento C., Pirtoli L., Salvatore M., Storto G. Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol. 2014 Oct; 190 (10): 925–32. doi:10.1007/s00066-014-0638-9.; https://www.siboncoj.ru/jour/article/view/564
-
13Academic Journal
Source: Research and Practical Medicine Journal; Том 4, № 3 (2017); 66-74 ; Research'n Practical Medicine Journal; Том 4, № 3 (2017); 66-74 ; 2410-1893 ; 10.17709/2409-2231-2017-4-3
Subject Terms: лучевые повреждения, hypofractionation, radiation therapy, overall survival, local recurrence, cosmetic results, radiation damage, гипофракционирование, лучевая терапия, общая выживаемость, локальные рецидивы, косметические результаты
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/201/193; Каприн А.Д., Старинский В.В., Петрова Г. В. Состояние онкологической помощи населению России в 2015 году.М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2016, с. 5, 31, 198.; McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10‑year recurrence and 20‑year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21; 383 (9935): 2127–35. DOI:10.1016/S0140–6736 (14)60488–8. Epub 2014 Mar 19.; Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10‑year recurrence and 15‑year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12; 378 (9804): 1707–16. DOI:10.1016/S0140–6736 (11)61629–2; Mortimer JW, McLachlan CS, Hansen CJ, Assareh H, Last A, McKay MJ, et al. Use of hypofractionated post-mastectomy radiotherapy reduces health costs by over $2000 per patient: An Australian perspective. J Med Imaging Radiat Oncol. 2016 Feb; 60 (1): 146–53. DOI:10.1111/1754–9485.12405; Rudat V, Nour A, Hammoud M, et al. Better compliance with hypofractionation vs. conventional fractionation in adjuvant breast cancer radiotherapy. Strahlenther Onkol. 2017; 193 (5): 375–384. DOI:10.1007/s00066–017–1115‑z; Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology. 2005; 69 (3): 214–23. DOI:10.1159/000087909; Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society For Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81 (1):59–68. DOI:10.1016/j.ijrobp.2010.04.042; Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010 Feb 11; 362 (6): 513–20. DOI:10.1056/NEJMoa0906260.; Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006 Jun; 7 (6): 467–71. DOI:10.1016/S1470–2045 (06)70699–4; Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et.al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10‑year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct; 14 (11): 1086–94. DOI:10.1016/S1470–2045 (13)70386–3; Haviland JS, Bentzen SM, Bliss JM, Yarnold JR, START Trial Management Group. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiother Oncol. 2016 Dec; 121 (3): 420–423. DOI:10.1016/j.radonc.2016.08.027; Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct; 1 (7): 931–41. DOI:10.1001/jamaoncol.2015.2666; Koukourakis MI, Tsoutsou PG, Abatzoglou IM, Sismanidou K, Giatromanolaki A, Sivridis E. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74 (4): 1173–80. DOI:10.1016/j.ijrobp.2008.09.016; Karasawa K, Kunogi H, Hirai T, Hojo H, Hirowatari H, Izawa H, et al. Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients. Breast Cancer. 2014 Jul; 21 (4): 402–8. DOI:10.1007/s12282–012–0406–6; Linares I, Tovar MI, Zurita M, Guerrero R, Expósito M, Del Moral R. Hypofractionated Breast Radiation: Shorter Scheme, Lower Toxicity. Clin Breast Cancer. 2016 Aug; 16 (4): 262–8. DOI:10.1016/j.clbc.2015.09.012; Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule. Comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015 Oct;1 (7):918–30. DOI:10.1001/jamaoncol.2015.2590; Гладилина И.А., Клеппер Л.Я., Ефимкина Ю.В., Высоцкая И.В., Петровский А.В., Козлов О.В., и др. Гипофракционированный ускоренный режим лучевой терапии у больных после органосохраняющих операций по поводу I–IIА стадий рака молочной железы. Опухоли женской репродуктивной системы. 2016; 12 (3): 17–22. DOI:10.17650/1994–4098–2016–12–3-17–22; Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med. 2015 Jul 23;373 (4):317–27. DOI:10.1056/NEJMoa1415369; Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23; 373 (4): 307–16. DOI:10.1056/NEJMoa1415340; NCCN Guidelines Version 1.2017 03/10/17, 96–99.; Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5: v8–30. DOI:10.1093/annonc/mdv298; Shelley W, Brundage M, Hayter C, Paszat L, Zhou S, Mackillop W. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 2000 Jul 15;47 (5): 1219–28. DOI:10.1016/S0360–3016 (00)00567–8; Каприн А.Д., Галкин В.Н., Жаворонков Л.П., Иванов В.К., Иванов С.А., Романко Ю. С. Синтез фундаментальных и прикладных исследований — основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017; 26 (2): 26–40.; https://www.rpmj.ru/rpmj/article/view/201
-
14Academic Journal
Authors: ПАНЬШИН Г.А., ХАРЧЕНКО Н.В., МИЛЮКОВ С.М., ИЗМАЙЛОВ Т.Р.
File Description: text/html
-
15Academic Journal
Source: Наука и здравоохранение.
Subject Terms: сәулелік ем, сүт безі обыры, breast cancer, лучевая терапия, hypofractionation, жедел әсер, острая реакция, гипофракционирование, гипофракцияландыру, рак молочной железы, radiation therapy, skin toxicity, 3. Good health
-
16Academic Journal
Source: Наука и здравоохранение.
Subject Terms: хрономодулирленген терапия, chronomodulated therapy, гипофракциониондау, хрономодулированная терапия, hypofraction, сәулелік токсикалық, бас және мойын обыры, 3. Good health, chemoradiotherapy, рак головы и шеи, radiation toxicity, гипофракционирование, head and neck cancer, химиялық сәулелік емдеу, лучевая токсичность, химиолучевое лечение
-
17Report
Authors: Шеффрес, Елизавета Викторовна
Contributors: Сухих, Евгения Сергеевна
Subject Terms: лучевая терапия, стереотаксическая радиотерапия, объемно модулированная лучевая терапия, аденокарцинома, гипофракционирование, radiotherapy, stereotactic radiotherapy, Volumetric Arc Therapy, adenocarcinoma, hypofractionation, 14.04.02, 539.16.04:615.84:616.65
File Description: application/pdf
Availability: http://earchive.tpu.ru/handle/11683/48023
-
18Academic Journal
Source: Наука и здравоохранение.
Subject Terms: гипофракциялау, breast cancer, лучевая терапия, косметологиялық нәтиже, cosmetic result, сәулелік терапия, косметический результат, гипофракционирование, hypofraction, сүт безінің қатерлі ісігі, рак молочной железы, radiation therapy, 3. Good health
-
19Academic Journal
Source: Наука и здравоохранение.
Subject Terms: recurrence, ұзақ мерзімді нәтижелер, лучевая терапия, hypofractionation, рецидив, отдаленные результаты, long-term results, сәуле терапия, radiation therapy, 3. Good health, breast cancer, сүт безі қатерлі ісігі, гипофракционирование, гипофракцияландыру, рак молочной железы
-
20Academic Journal
Source: Наука и здравоохранение.
Subject Terms: сәулелік ем, сүт безі обыры, лучевая терапия, hypofractionation, жедел әсер, бастапқы және шеткері нәтижелер, early and long-term results, radiation therapy, 3. Good health, breast cancer, ранние и отдаленные результаты, гипофракционирование, гипофракцияландыру, рак молочной железы
